Strativa Pharmaceuticals has entered into an agreement with Swedish Orphan Biovitrum (Sobi) for the development and commercialization of Nascobal cyanocobalamin (Vitamin B12) nasal spray in Europe. Sobi plans to begin development for European approval in early 2011 and will help to finance an upgrade of Strativa’s facilities necessary to meet EU regulations. QOL Medical, which had a pre-existing agreement with Sobi, sold worldwide rights for the product to Strativa in 2009. According to Strativa, Nascobal will be its first product marketed outside of the United States. Read the company’s press release.
European development deal for Strativa’s Nascobal
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
